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Abstract
Respiratory Syncytial Virus is a frequent cause of severe bronchiolitis in children. To improve our understanding of systemic
host responses to RSV, we compared BALB/c mouse gene expression responses at day 1, 2, and 5 during primary RSV
infection in lung, bronchial lymph nodes, and blood. We identified a set of 53 interferon-associated and innate immunity
genes that give correlated responses in all three murine tissues. Additionally, we identified blood gene signatures that are
indicative of acute infection, secondary immune response, and vaccine-enhanced disease, respectively. Eosinophil-
associated ribonucleases were characteristic for the vaccine-enhanced disease blood signature. These results indicate that it
may be possible to distinguish protective and unfavorable patient lung responses via blood diagnostics.
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Introduction
Most children become infected with respiratory syncytial virus
(RSV) within the first two years of their life. Infants infected with
RSV show disease courses that range from uneventful upper
respiratory tract symptoms to severe bronchiolitis requiring
mechanical ventilation [1,2]. Although several risk factors for
severe disease are known [3–5], including host genetic factors,
many aspects of host susceptibility are still poorly understood. In
previous studies we used gene expression analysis to characterize
the lung response upon primary and secondary RSV infection in
detail in a murine model [6,7], and showed a robust innate
immune response at day 1 and 2 after RSV infection. The
predominant signature of the primary infection was the rapid
innate immune response characterized by the induction of large
numbers of chemokines and interferon (IFN) regulated genes. In
mice protected against RSV by primary infection that were
subsequently challenged with RSV, this early innate response was
almost identical to the response in primary infection, but was
followed by a rapid decrease in time concomitant with viral
disappearance. In contrast, mice with formalin-inactivated RSV
(FI-RSV) vaccine-enhanced disease displayed a prolonged innate
immune lung response with characteristics of Th2 polarization.
In recent years, there have been several studies that applied
blood transcriptomics for lung inflammatory disease diagnostic
purposes [8–12]. However, eventual clinical implementation of
blood transcriptomics relies on the extent to which its results
represent molecular lung pathology during the disease course. In
the case of RSV, insight into the correlation between the lung and
blood response during primary RSV bronchiolitis may guide the
development of methods for blood-based identification and
monitoring of host responses as a proxy for the disease process
that is ongoing in the lung. Additionally, a more detailed insight
into which aspects of lung responses are represented at the
systemic (i.e. blood) level, is required to improve our understand-
ing of host responses to RSV infection in children. In this study, we
describe the comparison between gene expression responses in
lung, bronchial lymph nodes, and whole-blood in a mouse model
upon primary and secondary RSV infection. We identified an
innate immunity-associated gene set that gives correlated respons-
es in these three tissues and characterized the systemic signature of
the local lung infection. Next we focused on systemic signatures
that can distinguish mice with a distinct presentation of infection.
We identified gene blood gene expression signatures indicative of
acute infection, secondary immune response, and vaccine-
enhanced disease, respectively.
Materials and Methods
Ethics statement
This study was agreed upon by the Animal Experimentation
Ethical Committee of our institute under permit number
200700171. Animal handling in this study was carried out in
accordance with relevant Dutch national legislation, including the
1997 Dutch Act on Animal Experimentation.
Animal experiment
All experimental procedures have been described before [7] and
were performed in accordance with national and institute
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group) were infected intranasally with 10
6 pfu RSV type A2 or
mock 7 weeks before challenge, or intramuscularly injected with
10
7 pfu FI-RSV or FI-mock 7 and 3 weeks before challenge. At
day 0, mice were challenged intranasally with 10
6 pfu RSV. Mice
were sacrificed unchallenged or at day 1, 2, or 5. The right lung
and bronchial lymph nodes were collected in RNAlater (Applied
Biosystems) and used for RNA isolation according to described
methods [6,7]. Blood was collected in a K2-EDTA blood
collection tube (Terumo). Subsequently, 0.5 ml blood was added
to 1.3 ml RNAlater, stored overnight at 4uC, and until RNA
isolation stored at 220uC. Total RNA was isolated with the
Mouse RiboPure -Blood RNA isolation kit, followed by DNase
treatment with the DNA-free kit, and after ethanol precipitation
depleted for globin mRNA with the GLOBINclear -Mouse/Rat
kit (all blood RNA kits from Applied Biosytems). RNA
concentrations were measured using a NanoDrop Spectropho-
tometer (Thermo Scientific) and RNA quality was determined
using a Bioanalyzer (Agilent). Prior to further microarray analyses,
RSV infection was verified by realtime PCR on RNA isolated
from the lung as described [7].
Microarray analysis
RNA amplification and labeling were carried out with the
Amino Allyl MessageAmp II aRNA kit (Applied Biosystems)
according to the manufacturers’ instruction, using 1.5 mg of total
RNA as starting material. RNA samples from individual mice
(n=4–5 per group) were labeled and hybridized against a
common reference containing a labeled amino allyl-modified
aRNA pool of all samples isolated. Microarray slides containing
22,680 oligos from the Sigma-Compugen Mouse oligonucleotide
library (and appropriate controls) were spotted at the Microarray
Department of the University of Amsterdam. Arrays were scanned
at two wavelengths using a ScanArray 4000XL microarray
scanner (Perkin-Elmer). Following microarray scanning, median
Cy3 and Cy5 signal intensities per spot were determined using
Array Vision software (Imaging Research). Quality control was
performed on raw data by means of visual inspection of the
scanned images, as well as a check on the scatter and MA plots.
To control for possible batch effects during RNA isolation,
labeling, or hybridization, experiments were carried out according
to a randomized block design, so that samples for each biological
group were assigned evenly across handling days. As part of the
QC it was verified by PCA and ANOVA that no significant batch
effects could be found and (technical) variance due to possible
batch effects was smaller than (biological) variance within or
between experimental groups.
All raw and normalized microarray data are MIAME compliant
and were deposited at the ArrayExpress website (http://www.ebi.
ac.uk/arrayexpress/) under accession numbers E-TABM-826 and
E-TABM-1094.
Data analysis
Data analysis was performed in accordance with methods we
used previously [6,7]. Briefly, raw signal data from oligo-
containing spots were normalized in R using a three-step approach
of natural log-tranformation, quantile normalization of all scans,
and correcting the sample spot signal for differences in the
corresponding reference spot signal between arrays. Differentially
expressed genes were identified with ANOVA, using stringency
criteria of p,0.001 and a .2-fold induction (i.e. up-regulated by
challenge) unless indicated otherwise. This p-value corresponded
to a False Discovery Rate of ,5% for all three tissues. Gene
expression patterns were visualized in R and GeneMaths XT
(Applied Maths). Functional annotation and Gene Ontology (GO)
term overrepresentation were assessed using the DAVID func-
tional annotation tool (http://david.abcc.ncifcrf.gov/) [13]. Over-
representation of tissue-specific or literature-based functional gene
sets was determined in R using an in-house developed algorithm
based on the DAVID methodology, using gene sets extracted from
data at BioGPS website (http://biogps.gnf.org) [14,15] as well as
other relevant literature [16-19]. Additional functional annotation
was performed by textmining using Anni 2.1 (http://www.
biosemantics.org/anni/) [20]. Lists of regulated genes were
compared by calculating the cosine correlation, which for binary
lists equals R=Na&b/!(Na*Nb).
Enrichment for GO or other functional terms was further
visualized as a molecular concepts analysis by showing functional
terms and regulated genes per tissue as nodes and significant
(p,0.01) enrichment as edges. To compare expression changes
across days and tissues, a modular representation [17] was made of
gene expression changes. Modules included were relevant tissue
responses or disease course signatures as described in this study,
functional terms based on GO or Uniprot, and immune cell type-
based gene sets based on literature [15,17,18]. Median expression
changes per module were calculated and then visualized in
GeneMaths XT.
Results
In our previous study, gene expression in the lungs of mice upon
primary and secondary RSV infection was compared. In the
current study, the response in the bronchial lymph nodes and
blood from the same mice was determined. To identify the
systemic signature of the lung response, these blood and lymph-
node responses were first determined and compared to the
previously described lung response [7] of these mice.
In bronchial lymph nodes of primary RSV-infected mice, 192
genes were induced. Functional annotation showed that a large
percentage of genes were involved in the immune and inflamma-
tory response. Interferon signaling genes were up-regulated, as
well as genes associated with NK cells or cytotoxic lymphocyte
function (such as granzyme A and B). Additionally, at day 5, up-
regulation of immunoglobulin genes as well as several hematolog-
ical developmental genes was found (such as Pou2af1, Shh, Xbp1).
This indicates plasma cell maturation and the onset of antibody
production at this time point.
Blood responses showed significant up-regulation for 311 genes.
Among the regulated genes, there was significant enrichment for
immune and inflammatory response genes, especially interferon
responsive genes. These responses were more pronounced at day
5, when levels of regulation were comparable to those found in
lung (Figure 1). Additionally, we found up-regulation of a number
of (neutrophil) granulocyte-associated genes (such as Cd177, Fpr1,
Mmp8, Ncf1, Sell), indicating changes in the blood cell population
numbers.
The previously described lung signature induced upon primary
RSV infection encompassed 468 genes (p,0.001, minimally two-
fold induction). As reported previously [7], functional annotation
showed a significant enrichment for immune and inflammatory
response genes, and several involved mechanisms including
chemokine or cytokine activity, interferon responses, and antigen
processing. These genes were all highly expressed at days 1, 2, and
5 (Figure 1). Enrichment for biological process or cell type-
associated genes among genes regulated in lung, lymph node, or
blood is visualized in Figure 2. As can be seen from the Figure,
immune response, inflammatory response, and IFN-signaling are
enriched in all three tissues.
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compared across any of the days examined, the largest overlap
was seen between lung and blood. With 150 overlapping up-
regulated genes (R=0.39), this was larger than the overlap
between lung and lymph nodes (69 genes, R=0.23) or between
lymph nodes and blood (62 genes, R=0.25) (Figure 1). A group of
53 genes was identified which was induced in all three tissues in
response to RSV infection (Figure 1, Table 1). Gene expression
patterns between these genes were in good agreement, with
pairwise correlations based on these 53 genes always being larger
than 0.8. As described for the individual tissues, interferon
signaling was the predominant process found among the
functional annotations for these genes (Figure 2). Furthermore,
other immune-related functions such as inflammation and antigen
processing were found among these genes, as were cell cycle and
apoptosis (Figure 2). One chemokine (Cxcl9) was found among
these shared genes. A modular representation of gene expression
changes (Figure 3) shows that the median response for the shared
genes followed the time course kinetics in the three individual
tissues. The extent of regulation was most pronounced for lung,
followed by blood and lymph nodes (Figure 3).
Interferon signaling and an inflammatory response were also the
main processes among the 97 genes induced in lung and blood but
not in lymph nodes, indicating that responses in lung and blood
strongly overlap with respect to these processes. In contrast,
regulation of acute phase markers (e.g. Saa1, Saa2, Saa3, Lcn2) was
almost exclusively seen in the lung, as were most chemokines and
cytokines (Figure 2, Figure 3). Functional annotations seen only in
blood were (neutrophil) granulocyte-associated genes, whereas
immunoglobulin and plasma cell-associated genes are character-
istic for the genes that were only regulated in bronchial lymph
nodes (Figure 2, Figure 3).
For each of the three tissues, we also determined which genes
were down-regulated. In blood, we found only eight down-
regulated genes (p,0.001, minimally two-fold decrease). None of
these eight genes showed overlap with either the 241 genes down-
regulated in lung, or the 29 genes down-regulated in bronchial
lymph nodes. Therefore, in contrast to the up-regulated responses,
no shared down-regulated response could be identified.
During secondary infection of mice with RSV, the response was
much weaker than during primary infection, consistent with rapid
antibody-mediated viral clearance. Interestingly, especially the
shared IFN signature was not up-regulated in blood at day 5
(median ratio to control 1.08) indicating that this is clearly a
marker for acute infection (median ratio 3.61) (Figure 3). In mice
with vaccine-enhanced disease, this response was still detectable at
day 5 (median ratio 1.28), supporting the hypothesis that vaccine-
enhanced disease is mediated by an enhanced innate immunity
response in the presence of viral clearance. This is also reflected in
lung responses reported previously [7] as well as the expression of
a neutrophil-associated module (Figure 3).
After establishing that the gene expression response in the blood
of mice with primary RSV infection is, at least in part, a reflection
of the response that is raised at the site of infection, i.e. the lung,
we focused on blood signatures that can distinguish mice with a
distinct presentation of infection. Such signatures would allow
determination of the extent of lung infection through blood
diagnostics. For this purpose we determined the blood signatures
of either a protective (secondary) response or an adverse (FI-RSV
enhanced) response. As these responses were less clear-cut than the
Figure 1. Comparison between lung, lymph node, and blood responses. The Venn diagram indicates the number of genes regulated in
common or specific for each of the three tissues across any of the days examined. The heatmap indicates gene expression changes relative to the
median of the unchallenged group on days 1, 2, and 5.
doi:10.1371/journal.pone.0021461.g001
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criteria by making these slightly less stringent (p,0.001, induction
. 1.41-fold (i.e. a half log2-step)). We found five such markers for
the secondary response (IgG1, Cxcr3, Eaf2, 3110040K02Rik,
4921506M07Rik), and four for the vaccine-enhanced disease
(Ear1, Ear2, Ear3, Ear6). The former of these sets showed specific
induction in mice with secondary infection (median ratio = 1.71
versus 0.97 in primary infection or 1.09 in vaccine-enhanced
disease) (Figure 3) whereas the effects in the latter were specific for
the vaccine-enhanced disease (median ratio 5.53 versus 1.03 in
primary and 1.16 in secondary response) (Table 2, Figure 3).
Remarkably, the identified markers for vaccine-enhanced disease
were all eosinophil-associated ribonucleases, which is in agreement
with the Th2-polarized response found in the lung.
Discussion
The aims of our studies were two-fold. First, we wished to
establish if the systemic gene expression response to infection,
which can be measured in the blood, is a reflection of the local
response that is ongoing in the lung. Our studies show that over
30% of the genes induced in mouse lungs upon RSV infection
were also regulated in the blood transcriptome. A shared set of
biologically relevant genes was identified. Second, we used blood
transcriptomics to distinguish mice with a distinct presentation of
infection. Indeed, favorable and unfavorable responses could be
distinguished: induction of IFN regulated genes was indicative of
acute infection and absent during secondary infection whereas
induction of eosinophil-associated ribonuclease (Ear) genes was
indicative of vaccine-enhanced disease (Table 2, Figure 3).
The systemic signature identified in our study is in line with a
study in humans by Fjaerli et al. [8], who used microarray and
quantitative real-time PCR to study blood gene expression
responses to RSV. Their study reported significant differential
expression for 30 genes, including several interferon responsive
genes, in infants hospitalized with RSV bronchiolitis that did not
require artificial ventilation. Their controls were infants from the
same birth-cohort that never suffered from RSV bronchiolitis and
did not suffer from RSV infection at the time of blood sampling.
Although our studies were performed in mice, it is interesting to
note that Ifi27, which they reported as the most strongly up-
regulated gene, was also found significantly up-regulated in our
study (6.96-fold). Additionally, we found significant up-regulation
for five other genes reported as up-regulated by Fjaerli et al. (Ifi44,
H28/Ifi44L, G1p2, Hp, Clu), the first three of these being IFN
regulated. These genes were most prominently regulated in our
groups of mice with primary RSV infection and probably reflect a
state of active viral replication in the lung. In mice that clear the
infection this response was less prominent. The fact that our data
in mice display similarity with responses described in infants
suggest a similar systemic signature of acute RSV infection in mice
and humans.
Interferon-regulated responses appear to be part of the innate
response to viral and to some extent to bacterial pathogens. Zaas
et al. [9] reported whole-blood gene expression signatures in
response to RSV, rhinovirus, and influenza, in a cohort of healthy
adult volunteers. These healthy volunteers all showed mild
symptoms upon RSV infection. Viral infection signatures allowed
to accurately discriminate viral infections from bacterial infections
(Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli)o r
uninfected controls, but were mutually very comparable. Of the
genes reported in at least one of their viral top-30 signatures,
twelve were also regulated in our blood data (Cxcl10, Gbp1, H28/
Ifi44l, Herc5, Ifi27, Ifi44, Ifit1, Ifit2, Ifit3, Ly6e, Socs1, Stat1), again
including mostly interferon responsive genes. Of these, Gbp1 was
only present in the RSV signature. Ramilo et al. [10] described
classifiers to distinguish between pediatric patients with acute
influenza, S. pneumoniae, S. aureus,o rE. coli infection. Their
influenza classifier genes showed mostly IFN regulated genes,
several of which (Ifi44, G1p2, Oas1, Zbp1) showed overlap with our
signature. By contrast, in their classifiers to distinguish bacterial
infections from influenza or between different bacterial infections,
practically no IFN regulated genes were found and only Stat1
overlapped with our blood signature. Predominantly IFN
regulated signatures were also reported by Thach et al. [11] in
basic military trainees with adenoviral febrile respiratory illness.
Additionally, IFN responses were found in peripheral blood of
cynomolgus macaques after smallpox infection [21]. Taken
together, these studies show the role of interferon responsive
Figure 2. Functional enrichment for lung, lymph node, and blood responses. Nodes represent tissue responses (pink), shared primary
response (red), GO/UniProt functional terms (yellow) and immune cell type (light blue). Edges represent significant (p,0.01) enrichment (dark blue)
or a subset relation (gray).
doi:10.1371/journal.pone.0021461.g002
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PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21461Table 1. Gene expression changes upon RSV infection in mice for the shared set of 53 genes in lung, lymph node, and blood on
days 1, 2, and 5.
Gene symbol Synonym
Lung
d1
Lung
d2
Lung
d5
Lymph
d2
Lymph
d5
Blood d2
primary*
Blood d5
primary
Blood d5
protective*
Blood d5
adverse* Primary function
5830458K16Rik Rtp4 10.70 6.50 5.64 4.39 3.51 4.95 8.09 1.39 2.57 unknown
Ccnd1 2.62 1.66 1.80 2.17 1.49 3.36 1.66 0.94 0.88 cell-cycle
Clec7a 1.09 1.95 2.29 1.35 2.32 2.96 4.02 1.07 1.43 inflammation
Cxcl9 19.27 4.36 15.28 3.29 3.14 1.31 2.18 1.01 1.28 chemokine
Daxx 5.83 2.44 3.23 2.00 1.60 1.31 2.10 1.05 0.95 apoptosis
G1p2 45.72 15.08 22.79 7.03 5.32 5.52 1.59 0.62 0.49 interferon
Gata3 1.91 1.46 2.26 1.59 2.18 1.06 2.27 1.23 1.04 inflammation
Gbp1 5.06 1.91 6.61 2.20 3.03 1.55 8.30 1.19 1.33 interferon
Gbp2 6.93 2.72 8.37 2.05 3.71 1.66 9.47 1.08 1.17 interferon
Gbp4 9.61 3.65 7.84 1.89 2.94 1.33 5.24 1.33 1.46 interferon
Gvin1 2.27 1.69 2.58 2.14 2.19 1.42 2.64 1.05 1.30 interferon
Gzmb 4.99 3.10 12.01 3.76 4.93 1.59 2.52 1.59 1.53 inflammation
H28 Ifi44L 9.95 6.50 7.48 3.03 3.04 2.08 4.21 0.98 1.13 antigen processing
H2-M3 2.78 2.40 2.66 2.01 1.63 1.45 2.80 1.07 1.51 antigen processing
Herc5 8.30 3.17 3.70 2.04 1.88 1.95 2.29 1.13 1.03 antigen processing
Ifi1 11.02 5.07 11.50 3.67 4.69 2.32 8.11 1.09 1.35 interferon
Ifi202b 19.89 9.47 10.52 2.75 3.21 1.78 4.46 1.23 1.39 interferon
Ifi203 8.02 3.68 4.74 2.26 1.78 1.20 2.34 1.06 1.00 interferon
Ifi204 18.43 10.24 12.93 2.36 2.52 1.60 3.60 1.11 1.40 interferon
Ifi44 29.77 15.43 12.00 4.26 3.16 3.40 5.32 1.22 1.15 interferon
Ifi47 5.86 2.31 4.96 2.32 2.35 1.36 5.52 0.84 1.23 interferon
Ifit1 30.41 9.17 10.59 4.53 3.99 8.96 6.13 1.01 0.92 interferon
Ifit3 22.57 8.33 7.71 3.99 3.26 3.69 5.70 1.05 1.28 interferon
Ifitm3 3.45 3.03 2.86 2.22 1.73 5.74 4.38 1.10 1.79 interferon
Igtp 8.77 3.47 12.06 2.47 4.50 2.40 3.66 1.15 1.23 interferon
Iigp2 7.99 3.08 10.02 2.37 3.75 1.98 3.68 1.06 1.15 interferon
Il18bp 10.52 5.03 11.27 1.82 2.52 1.58 7.55 1.02 1.42 inflammation
Irf7 28.88 12.41 12.18 9.17 4.43 8.97 3.37 0.57 0.62 interferon
Isgf3g Irf9 2.56 2.18 1.63 2.22 1.79 1.61 2.14 1.00 1.07 interferon
Ly6a 3.23 2.88 4.61 5.10 5.33 1.93 3.97 1.01 1.23 various functions
Ly6c 4.17 2.50 3.47 2.97 3.65 2.81 8.95 1.08 2.06 various functions
Ly6f 3.83 2.37 2.75 1.91 2.41 2.56 7.48 1.09 1.41 various functions
Mpa2 Gbp4 4.91 1.77 8.13 2.58 3.42 1.12 4.26 0.89 1.02 inflammation
Ms4a11 3.04 2.14 2.68 2.05 1.75 1.22 2.71 1.10 1.75 various functions
Ms4a6d 15.59 11.16 12.27 4.40 2.83 2.00 6.87 1.37 2.54 various functions
Oas1a 12.65 6.42 7.80 2.41 2.19 2.44 3.95 1.09 1.64 DNA/RNA
Oasl2 10.46 6.23 6.53 1.88 2.13 5.41 10.38 1.10 1.25 DNA/RNA
Parp9 5.05 3.27 3.59 2.25 2.28 1.89 3.24 1.01 1.04 various functions
Pkib 1.58 1.73 2.12 2.40 2.33 1.27 2.87 1.20 1.16 various functions
Plac8 10.16 6.85 9.35 4.45 4.03 2.90 10.18 1.28 3.10 unknown
Rbm3 1.83 1.58 2.02 1.94 2.60 1.38 2.23 1.19 1.18 DNA/RNA
Samhd1 3.15 1.57 3.80 2.42 3.05 1.40 5.27 1.30 1.59 inflammation
Serpina3g 9.29 6.06 21.83 3.06 5.42 1.46 13.41 0.99 1.39 apoptosis
Six2 2.93 1.93 3.26 2.02 2.67 1.19 2.77 1.01 1.16 DNA/RNA
Slfn1 3.75 2.90 3.56 2.65 2.13 2.24 3.63 1.18 1.38 cell-cycle
Slfn3 7.72 3.05 4.63 2.78 2.11 2.27 4.18 0.68 0.86 cell-cycle
Slfn4 24.47 13.55 8.11 4.44 3.41 7.14 12.16 1.09 1.85 cell-cycle
Socs1 4.04 1.69 6.85 1.90 2.38 1.02 2.74 0.98 1.08 inflammation
Systemic Signature of RSV Response
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infection or other febrile illness and that the blood response in
humans and in murine models displays extensive similarities.
The finding that interferon signaling is involved in the gene
expression response in lung and blood, but also to some extent in
lymph nodes, is in agreement with previous studies that found a
pivotal role for the innate immune system in RSV clearing and
susceptibility to severe disease [6,7,22]. Indeed, for several shared
genes whose primary function is annotated to other pathways
(Table 1), there is evidence for interferon-dependent regulation, or
such regulation can be inferred through interferon-dependent
regulation of closely related homologs. Examples of this include
two oligoadenylate synthetase genes (Oas1a, Oasl2) [23], and three
slafen family members (Slf1, Slf3, Slf4) [24]. Altogether, for 38
genes such an association could be established. Moreover, when
promoter sequences of the remaining genes were examined (using
the oPOSSUM software at www.cisreg.ca/oPOSSUM [25]), two
IRF1 transcription factor binding sites were found upstream of the
Pkib gene, suggesting that even more genes might be regulated by
interferon signaling.
Besides other viral response signatures, the systemic IFN
signature reported in this study showed significant overlap with
blood signatures found in patients with systemic lupus erytroma-
tosus (SLE) [17], and LPS response in mice [26]. By contrast, this
overlap was not (or not significantly) found in patients with
juvenile idiopathic arthritis [27] or with an ionizing radiation [28]
or chemotherapy [26] response. Recently, Berry et al. [12]
reported an IFN-inducible whole-blood gene expression signature
that distinguishes active tuberculosis from latent tuberculosis or
healthy controls. Furthermore, in the study by Ramilo et al. [10]
about one third of patients with bacterial infections displayed
elevated expression levels of IFN regulated genes, although the
authors indicate it is unclear if these might have an undiagnosed or
preceding viral infection. Thus, although IFN responses seem to
be an essential part of the antiviral response both in humans and in
murine models, these studies indicate that it is not specific (nor
clearly aspecific) for viral infections. Confirmation of RSV or other
viral infections in clinical diagnostics therefore needs to come from
assays specific for detection of individual viruses. Conversely, host
blood signatures indicative of severe RSV infection may not be
specific for RSV infection and may be a marker of disease severity,
irrespective of the causative virus.
In the study by Zaas et al. [9], expression of IFN blood
signatures distinguished between mild symptomatic and asymp-
Gene symbol Synonym
Lung
d1
Lung
d2
Lung
d5
Lymph
d2
Lymph
d5
Blood d2
primary*
Blood d5
primary
Blood d5
protective*
Blood d5
adverse* Primary function
Socs3 2.70 2.25 3.54 2.23 1.77 1.63 2.45 1.17 1.32 inflammation
Stat1 6.46 3.62 6.86 2.62 3.88 1.32 5.06 1.18 1.56 interferon
Tgtp 16.07 5.28 19.28 3.67 4.53 3.68 5.14 1.05 1.03 inflammation
Xmr 3.72 2.67 3.75 2.53 2.44 2.10 6.98 1.13 1.77 cell-cycle
Zbp1 12.64 6.80 10.96 3.67 3.67 1.88 4.69 1.04 1.11 DNA/RNA
Blood data are indicated as follows: primary, primary RSV infection response; protective, secondary RSV infection response; adverse, FI-RSV vaccine-enhanced response.
Data for lung and lymph node are all responses to primary RSV infection. Values are given as ratios between infected and control.
doi:10.1371/journal.pone.0021461.t001
Table 1. Cont.
Figure 3. Module comparison of expression responses. Figures indicate the median response per module. Background color indicates the
extent of up- (red) or down-regulation.
doi:10.1371/journal.pone.0021461.g003
Systemic Signature of RSV Response
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21461tomatic cases, and a similar IFN signature was also found in
hospitalized children described by Fjaerli et al. [8]. Because these
two studies used a different study design and age groups and both
a relatively homogenous case and control groups, it is not possible
to determine to what extent IFN signatures correlated with disease
severity within or between these groups. By way of comparison,
expression of IFN signatures has been found to correlate with
disease severity in SLE [17] and tuberculosis [12]. Also, in our
study, after secondary infection with RSV the magnitude of the
shared IFN signature response differs from that of the primary
response, and additionally differs between a protective and an
adverse response. This suggests our blood signature might be
useful in a blood-based diagnostic or even prognostic application.
Moreover, a signature consisting of all IFN-dependent genes
regulated in blood (51 out of 311 genes, 38 overlapping with the
shared response) also shows differential expression between
primary, protective, and adverse responses (Table 2). However,
both our mouse study and human literature evidence to date are
insufficient to determine to what extent blood signatures are
indicative of RSV disease severity in children. Further studies will
therefore be needed with suitable cohort groups that also allow
addressing issues such as sensitivity towards other kinds of blood-
detectable disease or stress responses.
Our results suggest that blood-based mRNA analysis can be
used to recognize an unfavorable secondary Th2 response in case
of vaccine-enhanced disease. Ear1/2/3/6 expression was a typical
characteristic of the blood transcriptome during vaccine-enhanced
disease following RSV challenge in mice who previously received
the formaline-inactivated RSV vaccine. These genes are associated
with eosinophils and allergic asthma, and are involved in host
response against respiratory viral pathogens [29,30]. This also
applies to their corresponding human orthologs RNASE2 and
RNASE3 [29,30]. If the findings of our study can be translated to
humans, this may provide a powerful tool to assess safety of any
future RSV vaccine tested in humans. In particular, induction of a
Th2-biased response through the vaccine may be revealed at early
stage of vaccine development.
Taken together comparison of our murine data with human
literature data indicates that it may be possible to deduce patient
lung responses via the blood compartment. Distinct profiles of
blood biomarker genes are indicative of acute inflammation,
protection, and vaccine-enhanced disease in mouse RSV models.
Although for each of these signatures, specificity and relevance for
disease severity warrants further studies, this opens up possibilities
for studies aimed at predicting vaccine safety. Further translation
of such non-invasive testing methods to children may allow better
disease monitoring and treatment.
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